Irampanel
Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker. It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication. Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned, and the drug was ultimately never marketed.
primaryTopic
Irampanel
Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker. It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication. Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned, and the drug was ultimately never marketed.
has abstract
Irampanel (INN, code name BIIR ...... was ultimately never marketed.
@en
ATC prefix
CAS number
206260-33-5
IUPAC name
N,N-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine
@en
PubChem
thumbnail
Wikipage page ID
44,909,835
Wikipage revision ID
736,845,314
ChEMBL
ChemSpiderID
molecular weight
3.09362e+2
smiles
CNCCOc1ccccc1c2ncc3ccccc3
StdInChIKey
QZULPCPLWGCGSL-UHFFFAOYSA-N
subject
comment
Irampanel (INN, code name BIIR ...... was ultimately never marketed.
@en
label
Irampanel
@en